Neurostimulation and implantable drug delivery reach critical mass and promise continued rapid growth
This article was originally published in Clinica
The combined neurostimulation and implantable drug delivery businesses now represent a $540 million worldwide market, growing at 25% to 30% a year. They have the potential to grow at this rate for the next five years, but they would still barely penetrate what is conservatively calculated to be a potential $3 billion to $5 billion market.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.